As we turn toward the NASS meeting, it’s a good time to recap spine-related implants and biologics that were granted this designation in 2024.
The Numbers
The top ten most acquisitive orthopedic companies since 2016 are more focused on technology than the rest of the market.
While orthopedic growth rates slowed in the first half of 2024, the market’s volume and demand remain healthy.
Orthoflash®
NanoBone is a next-generation osteoinductive bone graft comprising nanostructured hydroxyapatite for remodelling bone.
September 12, 2024
,
The M-ARS technique offers a more natural approach to ACL reconstruction than traditional round-graft-tunnel single-bundle techniques.
September 12, 2024
,
The company has passed 10,000 total shoulder replacement procedures and closed $20 million in equity and venture debt financing.
September 11, 2024
,
The novel Right-Angle Drill is designed to improve tibia preparation prior to implantation of the APEX 3D tibia implant.
September 11, 2024
,
The first patient has been treated in the Phase I/II OASIS Trial, a study evaluating the safety and effectiveness of OsteoAdapt SP in spinal fusion procedures.
September 11, 2024
,
Competitive Landscape
ORTHOWORLD Experts talk you through market forecasts, company sales and key trends.
Industry Voices
